109 completed, 45 recruiting, 43 unknown, 24 terminated. 79 Phase 2, 65 Not applicable, 39 Phase 1, 25 Phase 3, 3 Early Phase 1.
Follow Laryngeal Neoplasms: new trials by email Literature Review of Laryngeal Neoplasms trials Research Report on Laryngeal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-10-26 | 2026-10-21 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-09-30 | 2026-08-13 |
| Intraoperative Methadone for the Management of Postoperative Pain in Patients With Head and Neck Cancers Electronic Health Record Review, Fentanyl, Laryngoscopy - Head and Neck Carcinoma, Hypopharyngeal Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 58 | 2026-09-22 | 2026-10-05 |
| Thermotherapy for Head and Neck Cancer Patients Thermotherapy, Radiotherapy, Concurrent chemoradiation - Head and Neck Cancer, Oropharyngeal Carcinoma | Phase 1 | Recruiting | Erasmus Medical Center | 30 | 2026-09-01 | 2026-09-02 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions Hypopharyngeal Cancer, Laryngeal Cancer | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3000 | 2026-04-30 | 2026-09-02 | |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer Biospecimen Collection, Carboplatin, Cemiplimab - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 180 | 2026-04-24 | 2026-10-14 |
| Quality of Life and Functional Outcomes in Laryngeal Cancer Patients Quality of Life Assessment, Patient Satisfaction Assessment, Swallowing Function Assessment - Laryngeal Carcinoma, Quality of Life (QOL) | Not yet recruiting | Saglik Bilimleri Universitesi | 120 | 2026-04-02 | 2026-04-22 | |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) Toripalimab + Chemotherapy, Toripalimab, Chemoradiotherapy or radiation - Head and Neck Cancer, Squamous Cell Carcinoma | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 75 | 2026-02-18 | 2026-04-23 |
| Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC Camrelizumab, Paclitaxel, carboplatin - Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms | Phase 2 | Not yet recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 50 | 2026-02-01 | 2026-02-10 |
| CApecitabine Prior to TUmor Resection in Ent Oncology (CAPTURE) Capecitabine, Standard of Care (SOC) - Head Neck Cancer, Mouth Cancer | Phase 2 | Not yet recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 75 | 2026-01-01 | 2025-11-28 |
| Validation of End-to-End Difficult Airway Pathway Planning Algorithm (EAP-LC) No Interventions - Laryngeal Cancer, Difficult Airway | Not yet recruiting | Eye & ENT Hospital of Fudan University | 70 | 2026-01-01 | 2026-01-07 | |
| Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC) routines - Glottic Carcinoma, Supraglottic Carcinoma | Recruiting | Eye & ENT Hospital of Fudan University | 1000 | 2025-12-01 | 2025-12-04 | |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population Celecoxib, Erlotinib Hydrochloride, Imaging Procedure - Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 25 | 2025-08-07 | 2026-10-01 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) Sacituzumab Govitecan, Cetuximab - Squamous Cell Carcinoma of Head and Neck, Sinus Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-07-02 | 2026-02-19 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
Showing 20 of 256. Sign in to see all of them.
Hypopharyngeal Neoplasms (119) · Mouth Neoplasms (107) · Oropharyngeal Neoplasms (105) · Head and Neck Neoplasms (96) · Squamous Cell Carcinoma of Head and Neck (59) · Nasopharyngeal Neoplasms (44) · Carcinoma (32) · Esophageal Neoplasms (32) · Lung Neoplasms (25) · Salivary Gland Neoplasms (25) · Carcinoma, Non-Small-Cell Lung (24) · Stomach Neoplasms (20) · Pancreatic Neoplasms (19) · Pharyngeal Neoplasms (19)
Respiratory Tract Diseases (256) · Respiratory Tract Neoplasms (256) · Otorhinolaryngologic Diseases (255) · Otorhinolaryngologic Neoplasms (255) · Neoplasms by Site (254) · Laryngeal Diseases (244) · Neoplasms (243) · Head and Neck Neoplasms (160) · Stomatognathic Diseases (158) · Pharyngeal Diseases (157) · Pharyngeal Neoplasms (135) · Mouth Diseases (110) · Neoplasms by Histologic Type (104) · Neoplasms, Glandular and Epithelial (104) · Carcinoma (70)
Cisplatin (35) · Radiotherapy (23) · Magnetic Resonance Spectroscopy (18) · Cetuximab (17) · Specimen Handling (15) · Carboplatin (13) · pembrolizumab (13) · Docetaxel (12) · Fluorouracil (12) · Radiotherapy, Intensity-Modulated (12) · 1,2-diaminocyclohexaneplatinum II citrate (10) · Platinum (9) · Radiation (9) · Surgical Procedures, Operative (9) · Paclitaxel (8)
National Cancer Institute (NCI) (16) · M.D. Anderson Cancer Center (7) · Roswell Park Cancer Institute (6) · Mayo Clinic (5) · Memorial Sloan Kettering Cancer Center (5) · Emory University (4) · Fudan University (4) · Wake Forest University Health Sciences (4) · Washington University School of Medicine (4) · Atos Medical AB (3) · Dana-Farber Cancer Institute (3) · ECOG-ACRIN Cancer Research Group (3) · First Affiliated Hospital, Sun Yat-Sen University (3) · Groupe Oncologie Radiotherapie Tete et Cou (3) · Mansoura University (3)
United States (130) · China (21) · France (19) · Netherlands (11) · United Kingdom (10) · Canada (9) · Italy (8) · Egypt (6) · Germany (6) · Switzerland (6) · India (5) · Spain (4) · Taiwan (4) · Croatia (3) · Czechia (3)
Frans JM Hilgers, MD, PhD (3) · Benjamin Lallemant, MD (2) · Carter Van Waes, M.D. (2) · Ching-Ting Tan, MD, PhD (2) · Edward J. Damrose MD, FACS (2) · Genglong Liu (2) · Laura Q Rogers, MD, MPH (2) · Loren K Mell (2) · Martin Mahoney, MD (2) · Michiel Kroesen, MD, Dr. (2) · Raul Pellini, Doctor (2) · Xiayun He, M.D. (2) · Yu Wang, M.D. (2)
PMID 10924966, PMID 11127145, PMID 14511925, PMID 14668816, PMID 16597660, PMID 16672085, PMID 16794899, PMID 16823067, PMID 16849759, PMID 17293228, PMID 17709149, PMID 17822322, PMID 19525472, PMID 19687399, PMID 20439512, PMID 20447554, PMID 20830768, PMID 21246519, PMID 21266057, PMID 21775497, PMID 21831465, PMID 22030975, PMID 22241828, PMID 22252927, PMID 22319013, PMID 22847995, PMID 23199641, PMID 23341517, PMID 23541643, PMID 23733379, PMID 24452791, PMID 24481647, PMID 24821357, PMID 25965900, PMID 26062933, PMID 26135695, PMID 26611425, PMID 27165613, PMID 27986347, PMID 28179349, PMID 28253270, PMID 28623906, PMID 29032418, PMID 29149611, PMID 29346519, PMID 29374733, PMID 30412221, PMID 30663068, PMID 30850872, PMID 31178203
P30CA138292 (4), U10CA180820 (4), U10CA180868 (4), P30CA015083 (2), P30CA016056 (2), UM1CA186690 (2), 2008 (1), 2015 (1), 2023 (1), K01AT004415 (1), K24DC022077 (1), P30CA006516 (1), P30CA006973 (1), P30CA012197 (1), P30CA014520 (1)